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Background: Following the initial reports of Chronic Cerebrospinal Venous Insufficiency (CCSVI) and the purported
curative potential of venoplasty, (coined the ‘liberation’ procedure) Canadians living with multiple sclerosis (MS)
began to travel abroad to receive the unregulated procedure, often placing them at odds with their health
providers. The purpose of this study was to determine the factors influencing older MS patients’ decision to
undergo the procedure in order to develop more specific and targeted health information.
Methods: We performed secondary analysis of data collected as part of the ‘Canadian Survey of Health Lifestyle and
Aging with MS’ from people over the age of 55 years with MS symptoms for 20 or more years. The survey consisted of
self-reported information on impairments, disability, participation, demographics, personal and environmental factors.
In order to compare respondents who underwent the procedure to those who did not and to develop a predictive
model, we created a comparison group using a case–control algorithm, controlling for age, gender and education, and
matching procedure cases to controls 1:3. We used multivariate stepwise least likelihood regression of ‘a priori’ variables
to determine predictive factors.
Results: The prevalence of the ‘liberation’ procedure in our sample was 12.8% (95/743), substantially lower than
reported in previous studies of complementary/alternative treatments in MS. The predictive model contained five
factors; living alone (Odds ratio 0.24, 95%CI 0.09-0.63), diagnosis of anxiety (Odds ratio 0.29, 95%CI 0.10 - 0.84), rating of
neurologist’s helpfulness (Odds ratio 0.56, 95%CI 0.44 -0 .71), Body Mass Index (Odds ratio 0.93, 95%CI, 0.89 - 0.98) and
perceived physical impact of MS (Odds ratio 1.02, 95%CI 1.01 - 1.04).
Conclusions: Predictive factors differed from previous studies of complementary/alternative treatment use likely due
to both the invasiveness of the procedure and the advanced age of our study cohort. Our findings suggest that health
professionals should target information on the risks and benefits of unregulated procedures to those patients who feel
dissatisfied with their neurologist and they should include family members in discussions since they may be providing
the logistical support to travel abroad and undergo the ‘liberation’ procedure. Our findings may be applicable to others
with chronic disabling conditions who contemplate the user-pay unregulated invasive procedures available to them.
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Diagnosed in young and middle-aged adults during their
career and family-building years, multiple sclerosis
profoundly impacts health-related quality of life [1-3].
In 80% of cases, MS is characterized by an unpredict-
able relapsing-remitting course, affecting movement,
balance, sensation and vision [4]. Twenty five years
after disease onset, 90% of those with MS will have
significant functional limitation but the long term
consequences of the disease are highly variable among
individuals [5,6].
Recognized as an idiopathic autoimmune degenerative
disease, the specific etiology and pathophysiology of
MS is still under debate [7]. The theory of Chronic
Cerebrospinal Venous Insufficiency (CCSVI) emerged
in 2009 which purported that impaired venous drain-
age in the jugular and azygous veins created reflux of
blood in the deep cerebral veins which subsequently
induced MS inflammatory lesions [8]. In some regions
of the world, user-pay clinics began to provide the endo-
vascular treatments (venoplasty) to open obstructed areas
in the veins which was coined the ‘liberation’ or the
‘Zamboni’ procedure by some [9]. Recent results of
observational and randomized controlled trials [10,11]
suggest that CCSVI is a normal incidental finding that is
not related to MS lesions.
Canada has the fifth highest rate of MS in the world
[12] and when Canadian television media [13] reported
the ‘liberation’ procedure as a cure for MS, the response
from the MS community was unprecedented [9]. Despite
the invasive nature of the surgery and the associated
risks, it is believed that thousands of Canadians living
with MS began travelling abroad to undergo the procedure.
Health professionals and MS patients found themselves
often on opposite sides of the debate [14]. Three recent
studies, using qualitative methods, have reported that
Canadians living with MS decided to receive the procedure
because they lost faith in the Canadian health care system
[15,16]; they were encouraged by others who had received
it [15,16], and the procedure gave them hope [17,16].
Quantitative predictors of CCSVI procedure use have not
been described. There may be some parallels between pre-
dictors of CCSVI procedure and those of complementary
and alternative medicine (CAM). Previous studies have
shown that CAM users are typically highly educated,
middle-aged women [18,19]. They also tend to report
a low health-related quality of life, declare dissatisfaction
with their health care professionals, and express a desire to
have more control over treatment decisions [20-22].
However, following one attempt to create a predictive
model of CAM use in MS using a large national
registry, the authors suggested that a better model fit
could be achieved by including disease-related variables
and personal factors [18].We undertook this study to determine the factors
propelling the decision to travel abroad and obtain
the ‘liberation’ or CCSVI procedure among Canadians;
critical knowledge that could potentially assist health
care professionals in targeting the right information to
vulnerable patients. To determine the factors associated
with undergoing the ‘liberation’ procedure, we analysed
data from the ‘Canadian Survey of Health Lifestyle
and Aging with MS’ collected between May 2010 and




We performed secondary analysis of cross-sectional data
collected as part of the ‘Canadian Survey of Health,
Lifestyle and Aging with MS’ which was approved by
Research Ethics Boards in eight Canadian provinces
(refer to Additional file 1). Details of the survey and
sampling are described elsewhere [20]. This purposeful
sample included older Canadians, over the age of 55 and
had MS symptoms for 20 or more years, who had
been recruited through MS clinics, MS Society chapters
and newspapers. The survey, constructed based on the
World Health Organization Framework [24], consisted of
patient-reported validated outcome tools and custom-
designed questions measuring impairments (eg. Hospital
Anxiety and Depression Scale [25]), disability (eg. Barthel
Index [26]), participation (eg. Frenchay Activities Index
[27]), health-related quality of life (eg. Multiple Sclerosis
Impact Scale [28]), and personal (eg. Personal Resource
Questionnaire-2000 [29], and Simple Lifestyle Indicator
Questionnaire [30]) and environmental factors (eg. finances,
health care). One survey question asked participants to list
“supplements or alternative treatments for your MS now or
in the past (anything not given to you through a doctor’s
prescription such as liberation treatments, bee sting therapy
or herbal supplements)”. They were then asked to rate the
helpfulness of the therapy on a scale from 1-not at all help-
ful to 5- extremely helpful. They were also asked to list and
rate the helpfulness of health care professionals they have
worked with. Additionally, two open-ended questions at the
end of the survey asked respondents “From your point of
view, what are the most important things that help you live
long and healthy with MS” and “If you would like to make
any final comments about this questionnaire or the study
itself, please record them in the space provided below”.
Participants
We used two methods to identify respondents in the
survey database who underwent the ‘liberation’ procedure.
The first was by the response to the question about use
of alternative therapies (which included the ‘liberation’
procedure) and the second, by performing a key word
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spinal venous insufficiency’) of all response data.
In order to compare respondents who underwent
the procedure to those who did not and to develop a
predictive model, we created a comparison group
using a case–control algorithm. Each ‘procedure’ case
was matched to three controls (‘no procedure’) based
on gender, age (±3 years), and total years of formal
education (±3 years). The differences between the
group means of the case matching variables (age, gender,
and education) and their ability to predict the ‘liberation’
procedure were first confirmed to be insignificant using
ANOVA and simple linear regression respectively. After
determining minimum and maximum acceptable limits
for education and age for each ‘procedure’ case, we created
a Microsoft Excel pivot table identifying all possible
controls for each case. An equation was applied to select
three controls at random. These cases and controls were
moved into their own database (IBM SPSS v20) for analysis.
Data analysis
Quantitative
The characteristics of cases and controls were compared
using one-way ANOVA or in the case of binary variables,
chi-square. Since we aimed to identify factors which
influenced whether to undergo the procedure or not,
we identified ‘a priori’ explanatory variables based on
previous research [18,17,15] in five categories; (1) satisfac-
tion with conventional healthcare, (2) mental health,
(3) MS severity, (4) resources (personal and financial),
and (5) lifestyle/overall health (Table 1). In the first
step of building an explanatory model, each ‘a priori’
variable (independent variable) was separately entered
into a simple binary logistic regression with the
dependent variable, ‘liberation’ procedure (yes/no). In
the second step, only those variables that significantly
predicted ‘procedure’ or ‘no procedure’ (p < 0.05) were
entered into forward and backward stepwise likelihood
ratio multivariate regression. In both steps, colinearity
between variables was checked. We used the Hosmer
and Lemeshow Test to assess model fit in which a
non-significant p value indicates a good fit. Analysis was
performed in SPSS v20 with significance set at p < 0.05.
Qualitative
Since the database included answers to open-ended
questions about living with MS as well as unsolicited
comments, advice and stories from participants on many
subjects, we used key word searches of these data to
identify potential text related to the ‘liberation’ procedure.
Key words included ‘liberation’, ‘CCSVI’, ‘Zamboni’,
‘neurologist’, ‘health’, ‘medical’, ‘team’, ‘care’, ‘cure’, ‘treatment’,
‘procedure’, ‘profession’, ‘trust’, ‘government’, and ‘alternative’.
The text was reviewed to ensure that the discussionrelated to the ‘liberation’ procedure and then divided
by respondent group, ‘procedure’ or ‘no procedure’.
Two of the researchers (MP and OJM) independently
read the text multiple times to extract the essential
elements. We used a thematic content analysis approach
to identify key themes in the respondents’ accounts [31].
The coders each created an initial coding grid, then by
consensus collapsed or deleted redundant codes to create a
final thematic scheme. One researcher (OJM) then coded
all text according to the scheme and gathered quotes that
embodied the essence of the theme. Both researchers then
collaboratively described the key messages and chose
quotes that represented those messages.
Results
Quantitative findings
The 743 survey respondents ranged in age from 55 to
88 years (64.6 ± 6.18) and reported having MS symptoms
for 32.9 (±9.5) years. The number of women outnumbered
men 3.48:1. Ninety percent of respondents were either
retired or unemployed and 28% reported that they were
no longer able to walk or were bedridden. Respondents
had on average 1.5 years of post-secondary education and
85.2% of respondents reported having at least one comor-
bid condition. Seven hundred and nine people completed
the open-ended questions (95%). We identified 95 people
in the database who reported that they had received the
‘liberation’ procedure (12.8% of the entire sample).
Ninety-one participants indicated they had the ‘liberation’
procedure in the alternative therapies section of the survey
and four participants disclosed they had the procedure
in the final section of the survey open for comments.
Eighty-seven respondents rated the helpfulness of the
‘liberation’ procedure (1 = least helpful, 5 =most helpful).
Forty-nine (56%) described it as helpful while the remainder
were neutral or found it not helpful.
We successfully matched controls to cases 3:1 and
created a new database of cases and controls (n = 380).
The characteristics of the ‘procedure’ group and the ‘no
procedure’ group are outlined in Table 2 with no significant
differences in the matched variables using ANOVA and no
significant relationship of matched variables and obtaining
the ‘liberation’ procedure.
Following simple binary logistic regression analysis of
the ‘a priori’ explanatory factors, seven were significantly
predictive of receiving the ‘liberation’ procedure. Odds
ratios (EXP β) and 95% confidence intervals are indicated
in Table 3. The ‘procedure’ group provided significantly
lower ratings of their neurologists’ helpfulness (but not
significantly lower ratings of other health professionals).
They were also healthier with fewer co-morbid conditions,
lower reported body mass index and were less likely to be
diagnosed with anxiety; all these factors were predictive of
group assignment. Although we found no difference in
Table 1 Potential explanatory variables
Category Variable Category Variable
Satisfaction with conventional
health care
Number of alternative therapies (not liberation) MS severity Participation (FAI domestic)
Number of medications Participation (FAI leisure)
General practitioner rating Participation (FAI outdoor)
MS nurse rating Physical impact of MS (MSIS-29)
Physiotherapy and occupational therapy rating Psychological impact of MS (MSIS-29)
Neurologist helpfulness rating Years with MS
Mental health Diagnosed anxiety Disability (Barthel Index)
Diagnosed depression Lifestyle/Overall health Number of co-morbid conditions
Anxiety symptoms (HADS-A) Health habits (SLIQ)
Depression symptoms (HADS-D) Body Mass Index (BMI)
Resilience (RS) Resources Social support (PRQ-2000)
Fatigue Living situation
Financial resources
HADS-A or -D, Hospital Anxiety and Depression Scale –Anxiety or -Depression; RS, Resilience Scale; FAI, Frenchay Activities Index; SLIQ, Simple Lifestyle Indicator
Questionnaire; BMI, Body Mass Index; PRQ-2000, Personal Resource Questionnaire version2000.
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78.18 ± 1.42; procedure 73.50 ± 25.25), the ‘procedure’
group reported higher perception of the impact of their
MS and less participation in household activities of daily
living (ADL) measured by the FAI. Social support or
financial situation were not predictive of receiving the
‘liberation’ procedure, however we did find that living
situation was predictive, in that those who were living
alone were significantly less likely to have the procedure.
Before building a predictive model with the minimum
number of explanatory factors, we examined the correla-
tions between the factors (Table 4). As expected, there
were minimal to moderate correlations between related
variables (bolded in Table 4). Moderate correlations over
0.30 existed (and were expected) between physical
impact of MS and participation, between number of
co-morbid conditions and BMI and between number
of co-morbid conditions and anxiety diagnosis. We
conducted the model fit analysis adding and deleting
these correlated variables until we achieved the best
fit. There was no significant effect of colinearity.
All significant explanatory variables (Table 3) were
entered into forward and backward stepwise likelihood
ratio regression in order from most to least predictive (β).
The Hosmer and Lemeshow Test showed that the best
model fit included five variables (Table 5: chi square 9.94,
p = 0.267) with 77.9% overall correct prediction (32.9%Table 2 Participant Characteristics
Characteristic Procedure (n = 95) No Procedure (n = 285)
Sex 77 F/18 M 224 F/61 M
Age (yrs) 63.25 ± 5.63 63.69 ± 5.49
Total Education (yrs) 13.52 ± 2.52 13.32 ± 2.16correct procedure group, and 92.7% no procedure group);
only 8 cases misclassified as ‘no procedure’.
The model consisted of living situation (living alone),
diagnosis of anxiety, rating of neurologists’ helpfulness,
BMI and the score on the MSIS-29 Physical Impact
Scale. When participants were living alone, they were
76% less likely to have the procedure (EXP β 0.24).
Those diagnosed with anxiety (but not depression or
other comorbid conditions) were 71% less likely to have
the ‘liberation’ procedure (EXP β 0.29). When participants
rated their neurologist’s helpfulness as high, they were
44% less likely to have the procedure (EXP β 0.56). The
two remaining factors (BMI and MS Physical Impact) had
much lower, although significant, predictive value. Those
respondents with higher reported BMI were 7% less likely
to have the procedure (EXP β 0.93) and finally, if partici-
pants had a high MSIS-29 Physical Impact Score, they
were about 8% more likely to have the procedure
(EXP β 1.02). To ensure these findings were correct,
we performed the same analysis on the full dataset
(n = 743) with similar results (data not shown).
Qualitative findings
Using the key word search, we found 61 text strings
discussing the ‘liberation’ procedure; 34 ‘procedure’
group and 27 ‘no procedure’ group. The main themes
and their frequencies are outlined in Table 6.
Canadian healthcare, trust and credibility
The ‘procedure’ and ‘no procedure’ groups described
polar opinions about their trust in the Canadian healthcare
system. Members of the ‘no procedure’ group described
how they were fortunate to have the support of their
neurologists and family doctors; “good medical support
Table 3 Significant explanatory variables for ‘liberation’ procedure
Category Variable Procedure No Procedure EXP ß
Mean ± SD Mean ± SD (95% CI))
Satisfaction with Conventional Health Care Neurologist Helpfulness Rating (rated 1–5) 2.93 ± 1.46* 3.94 ± 1.09 0.54*
(0.43-0.66)
Mental Health Diagnosed Anxiety 5/95 (5.26%)** 45/285 (15.79%) 0.30***
(0.11-0.77)
MSSeverity Physical Impact of MS (MSIS-29) 64.46 ± 19.06* 55.32 ± 20.20 1.02*
(1.01-1.04)
Participation (FAI Domestic Activities) 12.88 ± 5.20*** 14.45 ± 5.22 0.95***
(0.91-0.99)
Lifestyle/Overall Health Number of Co-morbid conditions 1.92 ± 1.76** 2.61 ± 2.12 0.83**
(0.73-0.95)
Body Mass Index (BMI) 23.81 ± 4.66** 25.79 ± 6.07 0.94**
(0.91-0.98)
Resources Living Situation “I live alone” 8/95 (8.42%)* 68/285 (23.86%) 0.293**
(0.14-0.64)
*p < 0.001 **p < 0.01, ***p < 0.05.
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ship also commented how this trusted source was
their primary source of health information; “I trust
the MS Society’s [information]”. One respondent in
the ‘no procedure’ group described how she knew
better than “to surf on the computer” and was “skeptical
about new therapies”.
Participants who had the ‘liberation’ procedure expressed
frustration towards the government and health pro-
viders regarding the availability of the procedure in
Canada (n = 10). Only one participant in the ‘no procedure’
group expressed these concerns. Several respondents
from the ‘procedure’ group described how they were
willing to try new therapies but felt that physicians
and the MS Society were “too slow; too controlled by
the pharmacy companies and too short-sighted”. Those
returning to Canada after receiving the procedure abroad
felt that they were “on [their] own” and “let down by my







Neurologist Helpfulness Rating 1
Diagnosed Anxiety −0.015 1
Physical Impact of MS −0.268** 0.070 1
Participation (FAI Domestic) 0.203** −0.052 −0.5
Number of Co-morbid conditions 0.012 0.349* 0.033
BMI −0.029 0.076 0.041
Living Situation “I live alone” 0.005 −0.019 0.023
*p < 0.001, ** p < 0.01, ***p < 0.05.Hope for a cure
Participants uniformly described how they are still
“hoping for a cure” and one respondent added “so I
get my life back”. One participant in the ‘procedure’
group stated “I don’t give up and I always think that
there will be a cure for MS in the future so I do the best I
can until then.” For respondents in both groups, the
promise of a cure touted by the ‘liberation’ procedure
information was encouraging.
Perceived outcome of the procedure
Eleven participants in the ‘procedure’ group described
improvements in balance, fatigue and pain following the
‘liberation’ procedure. Several qualified their endorsement
by explaining that they were not entirely free of MS
symptoms as a result of the procedure. For example,
one respondent stated, “I used to see through a cloud
and now that cloud is gone. I feel that this was well











Table 5 Final model predicting the ‘liberation’ procedure
among older Canadians with MS
MODEL COMPONENTS ß EXP ß
(95% CI)
1. Living situation (living alone) −1.41 0.24
(0.09-0.63)
2. Diagnosed anxiety −1.23 0.29**
(0.10 - 0.84)
3. Neurologist helpfulness rating −0.58 0.56*
(0.44 - 0.71)
4. Body Mass Index −0.07 0.93***
(0.89 - 0.98)
5. MSIS Physical Impact Scale 0.02 1.02***
(1.01 - 1.04)
*p < 0.001, ** p < 0.01, ***p < 0.05.
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one ‘procedure’ group participant felt her husband had
initial improvements in “balance, energy, improved
walking, warm hands and feet and speech. These lasted
for six months but he has regressed since then.”
Desire for the procedure
Nine participants in the ‘no procedure’ group described
a desire to undergo the ‘liberation’ procedure. Several
stated that they had “nothing to lose” but they “do not
have the money to go.” They described feeling frustrated
while waiting until the procedure is made available in
Canada. One participant said, “Right now, I don’t see
any light at the end of the tunnel because Canadian
physicians and surgeons are not willing to support
the ‘liberation’ treatment that has had positive results
in other countries.”
Discussion
Although user-pay invasive, unregulated procedures are
available to those who seek them, this study is the first
to describe the prevalence and predictors of one such
procedure, the ‘liberation’ procedure among people with
MS. The purpose of this study was to understand why
older MS patients chose to have the ‘liberation’ procedure
in order to target and tailor health information for thoseTable 6 Frequency of themes by group
TOPIC Procedure No procedure
Canadian healthcare, trust and
credibility
16 16
Hope for a cure 5 2
Perceived outcome of procedure Positive = 11 0
Negative = 2
Desire for the procedure 0 9patients who may be more likely to undertake such
interventions. We used a mixed methods approach to
secondary data analysis from Canadian national survey
data. Using an age, gender and education-matched,
case–control algorithm, we created a 3:1 sample of
‘no procedure’ and ‘procedure’. Both groups (with and
without the procedure) were on average about 63 years
old with 1.5 years of post-secondary education, with
women outnumbering men, typical of MS demographics
in general (3.48:1 full database; 3.67:1 ‘no procedure’:
4.27:1 ‘procedure’). Our findings may be applicable to
others with chronic disabling conditions since the factors
that influenced decision-making among this MS cohort
may be similar to those considering surgical procedures
that are purported as the cure for spinal cord injury and
cancer, among others.
The prevalence of the ‘liberation’ procedure in our
sample was 12.8%, a quarter of recent reported CAM
use in Nordic countries among people with MS [32] and
less than half of the 30% current use of alternative therapies
reported by Marrie [18] among the North American
Research Consortium on Multiple Sclerosis (NARCOMS)
sample of 20,778 people with MS in North America.
Although there are other invasive procedures available for
purchase, such as unregulated stem cell transplants and
‘reconstruction’, advertised to treat conditions such as
cancer and spinal cord injury, the prevalence of these have
not been reported making it difficult to compare our results
to other cohorts. Clearly, use of CAM such as evening
primrose oil, vitamins or visiting a nutritionist or chiroprac-
tor is accessible and low risk thus it not surprising
that CAM use is much greater than an alternative
surgical procedure such the ‘liberation’ procedure.
In order to create a case–control database to develop
a predictive model of ‘liberation’ procedure, we first
determined that age, gender and educational level
were not different or significantly predictive of receiving
the ‘liberation’ procedure. We found that living alone,
diagnosis of anxiety, higher rating of neurologist’s
helpfulness, higher BMI and lower perceived physical
impact of MS reduced the respondent’s likelihood of
undergoing the procedure.
Our findings differ from previous research on
CAM use in MS. For example, MS patients who utilize
unconventional/CAM therapies are typically college
educated [18,19,32,33] middle aged females [18,19,32]
with higher than average income [32,34]. We found
no predictive ability of these previously reported
demographic factors (age, gender, education, finances)
in our model. Considering the cost of the procedure,
we were surprised that financial situation was not
predictive, however our previous qualitative findings
[15] suggest that some people overcame financial barriers
by fundraising in their communities. Gender was also not
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undergo the ‘liberation’ procedure as women. These
discrepancies may be related to the fact that we sampled
an older cohort and that factors predicting CAM use may
have little overlap with factors predicting a surgical
procedure such as the ‘liberation’ procedure.
Living alone was a novel predictor that has not been
described in CAM research thus far. Since we found that
neither personal resources (PRQ-2000) nor financial
resources were predictive, we think, based on our previous
qualitative findings [15,17] that those who live with others
have more practical support in the home to investigate,
plan and accompany the person with MS to travel abroad
for the procedure. We previously reported that in some
cases, people with MS felt strongly influenced by the
opinions of family and friends, however in the current
study, respondents indicated that they were quite
agreeable and in fact enthusiastic about the procedure
despite varying benefits. Qualitative findings from this
study concur with others suggesting that the procedure
fostered hope [16,17]. This suggests that the role of the
family should be taken into consideration when providing
patient education and initiating a discourse about the risks
and benefits of unregulated procedures, as family
members may influence health decision-making at
least in this older cohort of people with MS.
It was interesting that a diagnosis of anxiety (but not
anxiety symptoms measured by HADS-A) was associated
with less likelihood of receiving the procedure. Anxiety
was included in the full list of co-morbid conditions and
both factors (anxiety and comorbidity) were initially
predictive of ‘liberation’ using simple regression. On
further examination of data and model fit, we found
that the predictive ability of ‘number of comorbid
conditions’ was actually the contribution of anxiety
diagnosis and not other health conditions such as
heart disease or arthritis. We are the first to report
such a finding. We postulate that people with an anxiety
diagnoses were less likely to attempt the organization,
travel and risks required to undergo the procedure.
Our qualitative findings support that some people desired
the procedure even though they did not receive it.
People who reported lower BMI were significantly
more likely to have the procedure. According to Centers
for Disease Control and Prevention [35], the ‘no procedure’
group with a mean BMI of 25.8 would be classified as
overweight while the ‘procedure’ group at 23.8 would be in
the normal range. Since we found that BMI was positively
correlated with number of comorbid conditions, perhaps
respondents with a lower BMI may have fewer health risks
to consider when making decisions whether to undergo
the ‘liberation’ procedure. Our findings differ from those
reported by Schwartz and group that suggested that people
with MS with at least one comorbid condition were morelikely to use unconventional therapies [34]. This difference
may be related to the degree of risk associated with
typical unconventional therapies (supplements, diets etc.)
compared to the ‘liberation’ procedure.
The predictive ability of rating of neurologist’s helpfulness
was not surprising since our qualitative findings suggested
that neurologists were a target of frustration for patients
who wished to have the procedure in Canada and could
not. Snyder et al. [16] and Ploughman et al. [15] confirmed
that people who decided to undergo the procedure were
frustrated with the Canadian health system. Others have
reported that higher health care provider ratings were
either predictive of CAM use [33] or had no effect [34].
When Campbell and colleagues [33] investigated the
predictive effect of health care provider ratings on
CAM use, they found that satisfaction with care was
not predictive. However, their respondents rated their
overall satisfaction with all health care providers rather
than specific professionals as in our study. We also found
modest but significant correlation between rating of
neurologist helpfulness and the physical impact of MS
and household participation (Table 4), suggesting that
people with higher impact of MS (but not level of disability
measured by Barthel) feel greater dissatisfaction with
neurologists (but not family doctors, nurses or therapists).
In terms of health and MS severity, CAM users tend
to have lower self-reported physical health [18,19] or more
progressive disease [33]. MS patients who are CAM users
are also more likely to utilize more conventional healthcare
[18,34]. Although disability, measured by the Barthel Index
was not predictive in this study, the perceived physical
impact of MS measured by the MSIS-29 was predictive.
The inconsistencies between findings may be attributed to
the differences between CAM and invasive procedures
or the difference between the constructs of reported
disability, perceived impact of MS, perceived physical
health and perceived overall health. There may be a
disconnect between disability and perceived health
among this older cohort who have lived with MS for
more than 20 years as reported by others [2,3].
Although we used a mixed-methods approach in a
national survey to gain an understanding of factors
influencing the decisions surrounding the ‘liberation’
procedure, there are some limitations to the study.
First of all, we collected data at one point in time so we
are unable to make causal inferences. We performed
secondary analysis on quantitative and qualitative data
that was collected for another use so we may have
seen different results in a survey designed specifically
to investigate CCSVI. Furthermore since we did not
ask participants the date of their ‘liberation’ procedure, we
do not know the temporal relationship between having
the procedure and completing the survey. Opinions and
beliefs about the ‘liberation’ procedure could change over
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of age with MS symptoms for more than 20 years, making
our findings difficult to translate to a younger cohort.
Furthermore, it is likely that those who live in long
term care facilities and/or did not attend MS clinics
may be underrepresented.
Conclusions
To determine the factors associated with undergoing the
‘liberation’ procedure, we performed secondary analysis of
survey data collected during the height of the ‘liberation’
procedure controversy in Canada. The prevalence of the
‘liberation’ procedure in our sample was 12.8%, substantially
less than reported in studies of other CAM or unconven-
tional treatments in MS. The predictive model contained
five factors; living alone, diagnosis of anxiety, rating of neu-
rologist’s helpfulness, BMI and perceived physical impact of
MS. Predictive factors differed from previous studies of
CAM use likely due to both the invasiveness of the
procedure and the advanced age of our study cohort.
Our findings suggest that health professionals should
target information on the risks and benefits of unregulated
procedures to those patients who feel dissatisfied with
their neurologist and they should include family members
in discussions since they may be providing the logistical
support to travel abroad and undergo the ‘liberation’
procedure. Our findings may be applicable to others with
chronic disabling conditions who contemplate the user-
pay unregulated invasive procedures available to them.
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